Futura Medical PLC MED2002 Update (3021P)
November 16 2016 - 1:00AM
UK Regulatory
TIDMFUM
RNS Number : 3021P
Futura Medical PLC
16 November 2016
For immediate release 16 November 2016
Futura Medical plc
("Futura" or "the Company")
MED2002 Update
Futura Medical plc (AIM: FUM), the innovative healthcare company
focused on advanced transdermal technology, is pleased to announce
the outcome of the detailed analysis of the results of the recent
breakthrough clinical study of MED2002, its topical gel for
erectile dysfunction ("ED"), and to outline the Company's strategy
for the further development of the product following the Company's
recent fundraising.
Since the announcement of the clinical results on 7 September
2016, the Company has conducted extensive sub-analysis of the
clinical data. The clinical study used one dosage of the active
principle, 0.6mg of glyceryl trinitrate, and produced highly
statistically significant results in the mild ED patient group.
The sub-analysis has also showed statistically significant
results in the mild to moderate group and also suggests that an
increased strength dose, 1.2mg of glyceryl trinitrate, may increase
the gel's efficacy especially in the moderate and severe ED patient
groups.
All the existing oral medications for ED offer at least two dose
strengths to treat the different levels of ED severity experienced
by patients. Futura intends to adopt a similar treatment strategy
to optimise MED2002's potential commercial and therapeutic
benefits.
In parallel with ongoing out-licensing negotiations, the Company
is planning a further Phase III clinical programme for MED2002,
which will start recruiting patients following discussions in early
2017 with EU and US regulators. It is intended that the clinical
programme will include two dosage strengths of MED2002's active
principle: 0.6 mg and 1.2mg of glyceryl trinitrate.
James Barder, Futura's Chief Executive, commented: "We believe
the strategy of including two dosages of MED2002 in the remaining
clinical development program to potentially treat as wide a range
of ED sufferers as possible will maximise the potential of this
breakthrough ED treatment.
"This strategy is also mindful that, with MED2002's rapid speed
of onset and favourable safety profile, two dose strengths may
unlock the huge potential of an over the counter treatment in an
indication where only one in three men are prepared to go to a
doctor to seek treatment. The lower dosage of MED2002 could
potentially address the over the counter market whilst the higher
dose would be prescription only."
For further information please contact:
Futura Medical plc
James Barder, Chief Executive Tel: +44 (0) 1483 685
670
Email to: james.barder@futuramedical.com www.futuramedical.com
N+1 Singer (Nominated
Adviser and Broker)
Aubrey Powell / Liz Yong Tel:+44 (0) 20 7496 3000
For media enquiries please
contact:
Buchanan
Mark Court / Sophie Cowles Tel: +44 (0) 20 7466
/ Stephanie Watson 5000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops
innovative products for consumer healthcare. The Company is
developing a portfolio of products and its strategy is to license
their manufacture and distribution to major pharmaceutical and
healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCAKADBABDKQDD
(END) Dow Jones Newswires
November 16, 2016 02:00 ET (07:00 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2023 to Apr 2024